COMPANY PROFILE
| Price and Volume | |
|---|---|
| Recent Price | 6.79 |
| 52 Week High | 10.83 |
| 52 Week Low | 1.55 |
| Avg. Daily Vol. (Mil) | 0.90 |
| Beta (3 year) | 1.65 |
| Share Related Items | |
| Mkt Cap (Mil) | 319.40 |
| Shares Out (Mil) | 47.04 |
| Float (Mil) | 45.34 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.00 |
| Current Ratio | 6.20 |
| LT Debt/ Equity | 0.04 |
| Total Debt / Equity | 0.12 |
| Valuation Ratios | |
| Price Earnings | N.A. |
| Price/Sales | 3.63K |
| Price/Book | 3.59 |
| Price/Cash Flow | -4.40 |
| Per Share Data | |
| Earnings | -2.04 |
| Sales | 0.00 |
| Book Value | 1.89 |
| Cash Flow | -1.54 |
| Business Summary | |
|---|---|
| A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. | |
| General Information | |
| 3344 North Torrey PinesCourt
Suite 200 La Jolla, CA 92037 |
|
| www.orexigen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 42 | |
| CEO: Michael A. Narachi | |
| Short Interest | |
| Current Month (Mil) | 3.02 |
| Previous Month (Mil) | 2.87 |
| Short Interest Ratio (Days) | 4.60 |
| Management Effectiveness | |
| Return on Equity | N.A. |
| Return on Assets | -65.10 |
| Return on Investments | -79.00 |
| Profitability | |
| Gross Margin | N.A. |
| EBIT Margin | N.A. |
| Profit Margin | 0.00 |